Andrew G. Masoud
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Andrew G. Masoud has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Allan G. Murray
Department of Medicine, University of Alberta, Edmonton, Canada
3 shared publications - Gavin Y. Oudit
Department of Medicine, University of Alberta, Edmonton, Canada
3 shared publications - Colin C. Anderson
Department of Surgery, University of Alberta, Edmonton, AB, Canada
2 shared publications - Jiaxin Lin
Department of Surgery, University of Alberta, Edmonton, AB, Canada
2 shared publications - Lin Fu Zhu
Department of Surgery, University of Alberta, Edmonton, Canada
2 shared publications - Abul K. Azad
Department of Medicine
1 shared publication
Latest Publications
- Open Access
- 26 August 2025
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (1) , 79-90
Sacubitril suppresses experimental chronic heart allograft vasculopathy
- 26 August 2025
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (1) , 79-90
Open AccessSacubitril suppresses experimental chronic heart allograft vasculopathy
- Open Access
- 5 January 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 23 (2) , 202-213
Endothelial phosphoinositide 3-kinase-β inactivation confers protection from immune-mediated vascular injury
- 5 January 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 23 (2) , 202-213
Open AccessEndothelial phosphoinositide 3-kinase-β inactivation confers protection from immune-mediated vascular injury
- 18 November 2019
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 130 (1) , 94-107
Apelin directs endothelial cell differentiation and vascular repair following immune-mediated injury
Sustained, indolent immune injury of the vasculature of a heart transplant limits long-term graft and recipient survival. This injury is mitigated by a poorly characterized, maladaptive repair response. Vascular endothelial cells respond to proangiogenic cues in the embryo by differentiation to specialized phenotypes, associated with expression of apelin. In the adult, the role of developmental proangiogenic cues in repair of the established vasculature is largely unknown. We found that human and minor histocompatibility–mismatched donor mouse heart allografts with alloimmune-mediated vasculopathy upregulated expression of apelin in arteries and myocardial microvessels. In vivo, loss of donor heart expression of apelin facilitated graft immune cell infiltration, blunted vascular repair, and worsened occlusive vasculopathy in mice. In vitro, an apelin receptor agonist analog elicited endothelial nitric oxide synthase activation to promote endothelial monolayer wound repair and reduce immune cell adhesion. Thus, apelin acted as an autocrine growth cue to sustain vascular repair and mitigate the effects of immune injury. Treatment with an apelin receptor agonist after vasculopathy was established markedly reduced progression of arterial occlusion in mice. Together, these initial data identify proangiogenic apelin as a key mediator of coronary vascular repair and a pharmacotherapeutic target for immune-mediated injury of the coronary vasculature.
- 18 November 2019
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 130 (1) , 94-107
Apelin directs endothelial cell differentiation and vascular repair following immune-mediated injury
Sustained, indolent immune injury of the vasculature of a heart transplant limits long-term graft and recipient survival. This injury is mitigated by a poorly characterized, maladaptive repair response. Vascular endothelial cells respond to proangiogenic cues in the embryo by differentiation to specialized phenotypes, associated with expression of apelin. In the adult, the role of developmental proangiogenic cues in repair of the established vasculature is largely unknown. We found that human and minor histocompatibility–mismatched donor mouse heart allografts with alloimmune-mediated vasculopathy upregulated expression of apelin in arteries and myocardial microvessels. In vivo, loss of donor heart expression of apelin facilitated graft immune cell infiltration, blunted vascular repair, and worsened occlusive vasculopathy in mice. In vitro, an apelin receptor agonist analog elicited endothelial nitric oxide synthase activation to promote endothelial monolayer wound repair and reduce immune cell adhesion. Thus, apelin acted as an autocrine growth cue to sustain vascular repair and mitigate the effects of immune injury. Treatment with an apelin receptor agonist after vasculopathy was established markedly reduced progression of arterial occlusion in mice. Together, these initial data identify proangiogenic apelin as a key mediator of coronary vascular repair and a pharmacotherapeutic target for immune-mediated injury of the coronary vasculature.